SCHEMBL479544

SCHEMBL479544

O=C(O)c1ccc(Cl)nc1Nc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 5/20 0.57
KMT2A Q03164 6/20 0.51
MEN1 O00255 5/20 0.51
RAB9A P51151 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
MAPT P10636 3/20 0.46
GFER P55789 1/20 0.46
NGLY1 Q96IV0 1/20 0.46
FABP4 P15090 1/20 0.45
NPC1 O15118 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
GAA P10253 2/20 0.42
ALDH1A1 P00352 4/20 0.42
GMNN O75496 1/20 0.42
LMNA P02545 1/20 0.42
TTR P02766 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
PKM P14618 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25941912 0.87 KMT2A (0.43) DHODHKMT2AMEN1RAB9ASMN1; SMN2
SCHEMBL27389234 0.84 DHODH (0.41) DHODHKMT2AMEN1RAB9ASMN1; SMN2
SCHEMBL479776 0.84 PDE4B (0.46) DHODHKMT2AMEN1SMN1; SMN2MAPT
SCHEMBL10251065 0.84 AKR1C3 (0.51) KMT2AMEN1MAPTGAAALDH1A1
SCHEMBL30038771 0.83 CSNK2B (0.50) DHODHKMT2AMEN1SMN1; SMN2MAPT
SCHEMBL8171612 0.80 DHODH (0.57) DHODHKMT2AMEN1RAB9ASMN1; SMN2
SCHEMBL13190366 0.80 DHODH (0.57) DHODHKMT2AMEN1RAB9ASMN1; SMN2
SCHEMBL898592 0.79 GABRP (0.43) DHODHKMT2AMEN1RAB9ASMN1; SMN2
SCHEMBL894573 0.77 GAA (0.46) KMT2AMEN1RAB9ASMN1; SMN2MAPT
SCHEMBL27389248 0.77 GAA (0.45) DHODHKMT2AMEN1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120077041-A Tricyclic derivative compounds and use thereof 韩美药品株式会社 2025-05-30 CN disclosed
WO-2024080788-A1 NOVEL TRICYCLIC DERIVATIVE COMPOUND AND USES THEREOF 한미약품 주식회사 2024-04-18 WO disclosed
WO-2024080788-A1 NOVEL TRICYCLIC DERIVATIVE COMPOUND AND USES THEREOF 한미약품 주식회사 2024-04-18 WO disclosed
US-20120094986-A1 ANTICANCER DERIVIATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2012-04-19 US disclosed
US-20120094986-A1 ANTICANCER DERIVIATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2012-04-19 US disclosed
EP-2411367-A1 ANTICANCER DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-02-01 EP disclosed
WO-2010109123-A1 ANTICANCER DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-09-30 WO disclosed
US-20100222319-A1 NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094986-A1 ANTICANCER DERIVIATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF NAMPT, NQO1, NNT DHODH 130/4885KMT2A 1491/4885MEN1 677/4885
US-20100222319-A1 NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF NNT, NAMPT, NQO1 DHODH 631/4885KMT2A 1349/4885MEN1 1485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.